A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Pain Associated With Endometriosis.

Trial Profile

A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Pain Associated With Endometriosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2010

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Actual patient number (48) added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Planned end date changed from 1 May 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top